Type 2 Diabetes

Obesity rates have climbed nearly 50 percent since 1997, with as much as 30 percent of the population classified as obese. There is strong belief within the health care industry that obesity should be treated as a primary medical condition, with physicians playing a major role. Evidence suggests that patients are more likely to lose weight when they are advised by their primary care physicians to do so.

GLP-1 receptor antagonists have been associated with thyroid cancer in rodents, and in fact carry a boxed warning about the potential for cancer in humans. This leads many clinicians to ask if they should be concerned about using these drugs in patients who have or develop specific types of thyroid cancer

Dementia is linked to comorbid diabetes and psychiatric conditions like depression, according to research from University College London.

Sitagliptin appears to have beneficial systemic and adipose anti-inflammatory effects in combination antiretroviral therapy-treated HIV-positive adults with impaired glucose tolerance. The drug may prevent cardiovascular problems by reducing inflammation linked to heart disease and stroke in this patient population.

GI side effects compel many patients to stop GLP-1 agonist therapy. A new study identifies important risk factors to consider before prescribing.

Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.

The results of the largest study of its kind to date indicate that new antipsychotic medications-including quetiapine, olanzapine, and risperidone-do not appear to put women at additional risk of developing gestational diabetes, hypertensive disorders, or major blood clots that obstruct circulation, all conditions that often develop during pregnancy or with the use of older antipsychotic medications.

Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.

Implanting an electrical stimulating device to help patients with gastroparesis is less successful when patients also suffer from depression, anxiety, or other mental health problems, a Texas team reports.

Patients with gastroparesis may be helped with a combination of gastric electrical stimulation and surgery to widen the pylorus, a Texas team reports.

Patients who are obese may have a genetic makeup that causes their stomachs to empty faster than those of normal-weight people. Investigators say there is a drug that can help.

What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?

More than 13,000 physicians and cardiovascular team members attended the ACC 2015 meeting in San Diego on March 14-16, 2015. In this issue of Cardiology Review, we focus on 6 important studies presented at ACC 2015: LEGACY, OSLER, PEGASUS, EMBRACE-STEMI, MATRIX, and CoreValve.

Mortality in patients with type 1 diabetes mellitus (T1DM) is higher than in the general population, and whether mortality improves or alters with glycemic control is unknown.

When doctors diagnose patients with diabetes they are only at the beginning stages of treatment which will last patients for many years if not the rest of their lives. How they handle that process is just as important as the process itself.

For diabetes patients being diagnosed with the disease is a life altering event. How they are informed about their condition can make a world of difference in how they approach their treatment.

Patients with inflammatory bowel diseases are sometimes treated with immunosuppressive drugs, particularly if they have a significant co-morbidity. A Boston team of researchers found that when that co-morbidity is diabetes, patients are at greater risk of coming down with infections.

In early testing the bionic pancreas has shown strong results for treating patients with type 1 diabetes. Over the next two years more work will go into streamlining the device and further testing in hopes of receiving FDA approval.

The final version of the bionic pancreas will be a more compact device but the first version is a combination mobile technology and existing glucose monitors and insulin pumps.

Patients with type 1 diabetes could get a powerful new treatment tool as work continues on the development of a bionic pancreas. The device is still undergoing testing and tweaking but initial results have shown promise from an early model.

Our endo blogger has her theories about why doing what you thought you loved just seems to sap your soul.

There are several reasonable options for intensifying this patient's blood pressure treatment. Which one is optimal, though, given his labs and concomitant meds?

Allergy sufferers may refrain from voicing sniffle complaints once they hear the benefits associated with the warmer weather.

China's type 2 diabetes mellitus (T2DM) epidemic continues to be a pervasive, costly health care issue, with proportions surpassed only by epidemic here in the US. The majority of T2DM treatment guidelines recommend metformin as the first-line anti-hyperglycemic agent for diabetes management due to its relative safety, tolerability, and cost-effectiveness.

The American Diabetes Association published its revised Standards of Medical Care in Diabetes in April 2015. The American Association of Clinical Endocrinologists (AACE) also issued an updated guideline in April 2015.

Studies show that nutrient-dense yogurt may benefit individuals with lactose intolerance, constipation and diarrheal diseases, hypertension, cardiovascular diseases, diabetes, and certain types of cancer.

Some key classes of antidiabetes agents could play a dual physiologic role. Find out which ones hold most promise in this at-a-glance summary.

There is no shortage of treatments available for the treatment of type 2 diabetes, but a new medication could change the way some patients manage their disease and could have even further reaching effects in the future.

When patients are initially diagnosed with type 2 diabetes, clinicians usually recommend several lifestyle changes, including weight loss. Few studies have looked at weight changes in patients with type 2 diabetes around initial diagnosis, although it's clear that it is more difficult for patients with diabetes to lose weight than it is for others.

While we wait for results from FDA-mandated CV outcomes studies by SGLT2I makers, there is plenty of (positive) speculation.